Proapoptotic and growth-inhibitory role of angiotensin II type 2 receptor in vascular smooth muscle cells of spontaneously hypertensive rats in vivo

Hypertension

Volumn 35, Issue 5, 2000, Pages 1069-1073

  Tea, Bun Seng ^a   Der Sarkissian, Shant ^a   Touyz, Rhian M ^b   Hamet, Pavel ^a   DeBlois, Denis ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CHUM Hôtel Dieu ^*

Author keywords

Angiotensin II; Enalapril; Losartan; Muscle, smooth, vascular

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DNA FRAGMENT; ENALAPRIL; VALSARTAN;

ADOLESCENT; ANGIOTENSIN BLOOD LEVEL; ANIMAL MODEL; ANIMAL TISSUE; AORTA DISEASE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DRUG EFFECT; GROWTH INHIBITION; HYPERTENSION; HYPERTROPHY; MALE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; SPONTANEOUSLY HYPERTENSIVE RAT; VASCULAR SMOOTH MUSCLE;

EID: 0034043699     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.35.5.1069     Document Type: Article

References (36)

1. Timmermans PBMWM, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR. Saye JAM, Smith RD. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 1993; 45:205-251.
2. Horiuchi M, Akishita M, Dzau VJ. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension. 1999;33:613-621.
3. Pollman MJ, Yamada T, Horiuchi M, Gibbons GH. Vasoactive substances regulate vascular smooth muscle cell apoptosis: countervailing influences of nitric oxide and angiotensin II. Circ Res. 1996;79:748-756.
4. Yamada T, Akishita M, Pollman MJ, Gibbons GH, Dzau VJ, Horiuchi M. Angiotensin II type 2 receptor mediates vascular smooth muscle cell apoptosis and antagonizes angiotensin II type 1 receptor action: an in vitro gene transfer study. Life Sci. 1998;63:PL289-PL295.
5. Sabri A, Levy BI, Poitevin P, Caputo L, Faggin E, Marotte F, Rappaport L, Samuel JL. Differential roles of AT1 and AT2 receptor subtypes in vascular trophic and phenotypic changes in response to stimulation with angiotensin II. Arterioscler Thromb Vasc Biol. 1997;17:257-264.
6. Levy BI, Benessiano J, Henrion D, Caputo L, Heymes C, Duriez M, Poitevin P, Samuel JL. Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure. J Clin Invest. 1996;98:418-425.
7. Otsuka S, Sugano M, Makino N, Sawada S, Hata T, Niho Y. Interaction of mRNAs for angiotensin II type 1 and type 2 receptors to vascular remodeling in spontaneously hypertensive rats. Hypertension. 1998;32: 467-472.
8. Li JS, Touyz RM, Schiffrin EL. Effects of AT1 and AT2 angiotensin receptor antagonists in angiotensin II-infused rats. Hypertension. 1998; 31:487-492.
9. Walter SV, Hamet P. Enhanced DNA synthesis in heart and kidney of newborn spontaneously hypertensive rats. Hypertension. 1986;8:520-525.
10. Owens GK. Control of hypertrophic versus hyperplastic growth of vascular smooth muscle cells. Am J Physiol. 1989;257(6 pt 2):H1755-H1765.
11. Hadrava V, Kruppa U, Russo RC, Lacourciere Y, Tremblay J, Hamet P. Vascular smooth muscle cell proliferation and its therapeutic modulation in hypertension. Am Heart J. 1991;122:1198-1203.
12. Hamet P, Richard L, Dam T-V, Teiger E, Orlov SN, Gaboury L, Gossard F, Tremblay J. Apoptosis in target organs of hypertension. Hypertension. 1995;26:642-648.
13. deBlois D, Tea B-S, Dam T-V, Tremblay J, Hamet P. Smooth muscle cell apoptosis during vascular regression in spontaneously hypertensive rats. Hypertension. 1997;29:340-349.
14. Campbell DJ, Kladis A, Valentijn AJ. Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. J Cardiovasc Pharmacol. 1995;26:233-240.
15. Touyz RM, Endemann D, He G, Li JS, Schiffrin EL. Role of AT2 receptors in angiotensin II-stimulated contraction of small mesenteric arteries in young SHR. Hypertension. 1999;33:366-372.
16. Nakajima M, Hutchinson HG, Fujinaga M, Hayashida W, Morishita R, Zhang L, Horiuchi M, Pratt RE. Dzau VJ. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci U S A. 1995;92: 10663-10667.
17. Matsubara H. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res. 1998;83:1182-1191.
18. Viswanathan M, Tsutsumi K, Correa FMA, Saavedra JM. Changes in expression of angiotensin receptor subtypes in the rat aorta during development. Biochem Biophys Res Commun. 1991;179:1361-1367.
19. Keiser JA, Major TC, Lu GH, Davis LS, Panek RL. Is there a functional cardiovascular role for AT2 receptors? Drug Dev Res. 1993;29:94-99.
20. Farhy RD, Carretero OA, Ho K-L, Scicli AG. Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation. Circ Res. 1993;72:1202-1210.
21. Linz W, Scholkens BA. A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril. Br J Pharmacol. 1992;105:771-772.
22. Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, Carretero OA. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure: role of kinins and angiotensin II type 2 receptors. J Clin Invest. 1997;99: 1926-1935.
23. Berthiaume N, Hess F, Chen A, Regoli D, D'Orleans-Juste P. Pharmacology of kinins in the arterial and venous mesenteric bed of normal and B2 knockout transgenic mice. Eur J Pharmacol. 1997;333:55-61.
24. Fukuo K, Hata S, Suhara T, Shinto Y, Tsujimoto S, Morimoto S, Ogihara T. Nitric oxide induces upregulation of Fas and apoptosis in vascular smooth muscle. Hypertension. 1996;27:823-826.
25. Marcic B, Deddish PA, Jackman HL, Erdos EG. Enhancement of bradykinin and resensitization of its B2 receptor. Hypertension. 1999;33: 835-843.
26. Minshall RD, Erdos EG, Vogel SM. Angiotensin I-converting enzyme inhibitors potentiate bradykinin's inotropic effects independently of blocking its inactivation. Am J Cardiol. 1997;80:132A-136A.
27. Boulanger CM. Secondary endothelial dysfunction: hypertension and heart failure. J Mol Cell Cardiol. 1999;31:39-49.
28. Bayer IM, Adamson SL, Langille BL. Atrophic remodeling of the artery-cuffed artery. Arterioscler Thromb Vasc Biol. 1999;19:1499-1505.
29. Van Kleef EM, Fingerle J, Daemen MJ. Angiotensin II-induced progression of neointimal thickening in the balloon-injured rat carotid artery is AT1 receptor mediated. Arterioscler Thromb Vasc Biol. 1996;16: 857-863.
30. 1 receptor expression. Arterioscler Thromb Vasc Biol. 1996;16:1130-1137.
31. 2 angiotensin receptors in apoptosis in rat blood vessels. Hypertension. 1999;34: 617-624.
32. Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger T. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest. 1995;95:651-657.
33. Luscher TF. The endothelium in hypertension: bystander, target or mediator? J Hypertens. 1994;12:S105-S116.
34. Nora EH, Munzenmaier DH, Hansen-Smith FM, Lombard JH, Greene AS. Localization of the ANG II type 2 receptor in the microcirculation of skeletal muscle. Am J Physiol. 1998;275:H1395-H1403.
35. Safar ME, Laurent S. Behaviour of conduit arteries in hypertension. Clin Exp Hypertens. 1993;15:1033-1045.
36. Folkow B. "Structural factor" in primary and secondary hypertension. Hypertension. 1990;16:89-101.